Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL923017 | 0.71 | EGFR (0.54) | EGFRARPIK3CDPIK3CABAZ1A | |
| Hydrochloric Acid SCHEMBL25267663 | 0.66 | EGFR (0.67) | EGFRARPIK3CDPIK3CABAZ1A | |
| Benzene SCHEMBL28800798 | 0.65 | EGFR (0.65) | EGFRARPIK3CDPIK3CABRAF | |
| SCHEMBL28041954 | 0.65 | EGFR (0.69) | EGFRARPIK3CDPIK3CABAZ1A | |
| SCHEMBL4481815 | 0.65 | EGFR (1.00) | EGFRARPIK3CDPIK3CABRAF | |
| SCHEMBL24783500 | 0.65 | EGFR (0.69) | EGFRARPIK3CDPIK3CABAZ1A | |
| SCHEMBL23055235 | 0.64 | EGFR (0.68) | EGFRARPIK3CDPIK3CABAZ1A | |
| SCHEMBL27889999 | 0.62 | EGFR (0.59) | EGFRARPIK3CDPIK3CABAZ1A | |
| SCHEMBL5669684 | 0.62 | CHRNA7 (0.41) | — | |
| SCHEMBL24782968 | 0.61 | EGFR (0.68) | EGFRARPIK3CDPIK3CABRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | DERMIRA (CANADA), INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8445694-B2 | Hydrazonopyrazole derivatives and their use as therapeutics | DERMIRA (CANADA), INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Valocor Therapeutics, Inc. (CA) | 2011-09-29 | — | — | US | disclosed |
| US-7875728-B2 | tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death | Valocor Therapeutics, Inc. (CA) | 2011-01-25 | — | — | US | disclosed |
| US-7105503-B2 | Pyrazole compounds | QLT INC. (CA) | 2006-09-12 | — | — | US | disclosed |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | DERMIRA (CANADA), INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1450791-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | Kinetek Pharmaceuticals, Inc. (CA) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045379-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | KINETEK PHARMACEUTICALS, INC. (CA) | 2003-06-05 | — | — | WO | disclosed |
| US-20030060453-A1 | Pyrazole compounds | DERMIRA (CANADA), INC. | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237783-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | EGFR 777/4885AR 3962/4885PIK3CD 254/4885 |
| US-20140107125-A1 | HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS | CDK4, CCNI, BCL2 | EGFR 777/4885AR 3962/4885PIK3CD 254/4885 |
| US-20050272709-A1 | Immugenic compositions and diagnostic and therapeutic uses thereof | MKI67, CDK4, CCNC | EGFR 578/4885AR 3822/4885PIK3CD 139/4885 |
| US-20030060453-A1 | Pyrazole compounds | CCNC, MKI67, CDC25C | EGFR 876/4885AR 3768/4885PIK3CD 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.